Anti-TROP2 Antibody (Synonyms: RN927C antibody)

Cat. No.: HY-P991372 Purity: 96.44%: Data Sheet
COA

SDS

FAQs
Technical Support

Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer.

For research use only. We do not sell to patients.

Anti-TROP2 Antibody Chemical Structure

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

In Vitro

Anti-TROP2 Antibody (0.1-10 μg/mL; overnight) induces mitotic arrest in Trop-2-positive BxPC3 pancreatic cancer cells^[1].
Anti-TROP2 Antibody (0.004-267 nM; 4 days) potently kills a variety of Trop-2-expressing human tumor cell lines, with an IC₅₀ value reaching the sub-nanomolar range^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:	BxPC3 pancreatic cancer cells, SW620 colon cancer cells
Concentration:	0.1, 1, 10 μg/mL
Incubation Time:	overnight
Result:	Induced a dramatic increase in phosphorylated histone H3-positive cells in Trop-2-positive BxPC3 cells at 0.1 μg/mL, indicating widespread mitotic arrest. Caused BxPC3 cells to detach from slides due to cell death at 10 μg/mL. Showed no increase in phosphorylated histone H3 staining in Trop-2-negative SW620 cells at 10 μg/mL compared to untreated cells.

Cell Cytotoxicity Assay^[1]

Cell Line:	A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3, SW620
Concentration:	0.004-267 nM
Incubation Time:	4 days
Result:	Potently killed most Trop-2-expressing cell lines (A431, Fadu, OVCAR3, BxPC3, Calu-3, NCI-H292, NCI-H1650, HCC-827, MDA-MB-468, Colo205, SKBR3 cells), with IC₅₀ values of 0.202, 0.507, 0.56, 0.674, 0.533, 0.633, 1.92, 0.779, 0.773, 5.06, 0.42 nM. Showed no cytotoxicity toward Trop-2-negative SW620 cells, despite free PF-06380101 payload being active against SW620 cells with an IC₅₀ of 0.305 nM.

In Vivo

Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus) induces regression of BxPC3 pancreatic xenograft tumors in mice^[1].
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus administration/once every 2 weeks; 2 doses total) induces regression of mouse Pan0123 pancreatic PDX xenograft tumors^[1].
Anti-TROP2 Antibody (0.75-3.0 mg/kg; i.v.; single bolus) induces regression and eradication of Ova196756 ovarian PDX xenograft tumors in mice^[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus administration) induces sustained regression of TROP2 LG0476 lung cancer PDX xenografts in mice^[1].
Anti-TROP2 Antibody (1.5 mg/kg; i.v.; single bolus; repeated administration 63 days after the first dose) induces long-term regression of large CTG-1017 triple-negative breast cancer PDX xenografts in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17/SCID (female, 5-6 weeks old, pancreatic cancer xenograft with 2 million BxPC3 cells implanted subcutaneously)^[1]
Dosage:	0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
Administration:	i.v.; single bolus injection
Result:	Induced tumor regression at 1.5 mg/kg and 3.0 mg/kg doses. Inhibited tumor growth at 0.75 mg/kg dose compared to controls.

Animal Model:	CB17/SCID (female, pancreatic cancer PDX xenograft with 1-2 mm³ Pan0123 fragments implanted subcutaneously)^[1]
Dosage:	0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
Administration:	i.v.; single bolus injection/i.v.; every 2 weeks; 2 total doses
Result:	Induced tumor regression at all tested single doses, with the most persistent regression seen at higher doses.

Animal Model:	CB17/SCID (female, ovarian cancer PDX xenograft with 1-2 mm³ Ova196756 fragments implanted subcutaneously)^[1]
Dosage:	0.75 mg/kg; 1.5 mg/kg; 3.0 mg/kg
Administration:	i.v.; single bolus injection
Result:	Induced tumor regression at all tested single doses. Induced more persistent regression and tumor eradication at doses ≥1.5 mg/kg.

Animal Model:	CB17/SCID (female, lung cancer PDX xenograft with 1-2 mm³ LG0476 fragments implanted subcutaneously)^[1]
Dosage:	1.5 mg/kg
Administration:	i.v.; single bolus injection
Result:	Induced sustained tumor regression. Showed superior efficacy over gemcitabine treatment (tumor regrew sooner) and paclitaxel treatment (only partial growth inhibition).

Animal Model:	CB17/SCID (female, triple-negative breast cancer PDX xenograft with 1-2 mm³ CTG-1017 fragments implanted subcutaneously)^[1]
Dosage:	1.5 mg/kg
Administration:	i.v.; single bolus injection; repeated 63 days after first dose
Result:	Induced tumor regression lasting more than 60 days with the first single dose. Induced another long-duration tumor regression after retreatment of regrown tumors.

Gene ID

4070 [NCBI]

Accession

P09758

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-TROP2 Antibody]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 96.44%

Select Batch:

Data Sheet (265 KB) SDS (251 KB)

COA (231 KB) SDS-PAGE (133 KB) SEC-HPLC (103 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Strop P, et al RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Mol Cancer Ther. 2016 Nov;15(11):2698-2708. [Content Brief]

Anti-TROP2 Antibody Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-TROP2 AntibodyRN927C antibodyTROP2EGP-1M1S1GA733-1BxPC3 pancreatic cancer cellssolid tumorsmicrotubule inhibitornon-human primatePDX xenograftsTrop-2SW620 colon cancer cellsmitotic arrestHCC-827 non-small cell lung cancer cellsmicrotubule polymerizationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *